Search
Dec 9, 2023
Arcellx's CEO on Friday's #ASH23 topline release and his take on the BCMA field
Rami Elghandour compares Arcellx's estimated 28 month PFS to Carvykti and gives his take on the recent FDA notice about CAR-T.
Aug 30, 2023
Arcellx’s CMO gives an update on their BCMA program at the 2023 CAR-TCR Summit
Chris Heery describes the process relating to bridging therapy that enabled a partial clinical hold to lift.
Jan 11, 2023
Talking BCMA CAR-T at #JPM23
Arcellx CMO Chris Herry talks about BCMA CAR-T for multiple myeloma at #JPM23.
.png){kind=logo}
